leisure time -WSS

leisure time

author：comprehensive 2025-09-11 06:21:30 - browse：23

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Designating disabled people as health disparity population is crucial

hotspot

WSS

Stanford president's case begs question: Who takes blame?

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Caregivers of transplant patients call for more support, training

Biotech reporter’s notebook: A sunnier mood at JPM 2024

New menopause drug shows promise in relief for hot flashes

Judge rejects Trump's request to move Stormy Daniels hush

hotspot

leisure time

knowledge

23andMe had bad news about my health. I wish a person had delivered it

I learned firsthand about improving diversity in clinical trials

Apple is now the first public company to be valued at $3 trillion

Risky weight loss products often used by teens globally, per study

Dobbs anniversary: the lost opportunity of abortion as health care

Caregivers of transplant patients call for more support, training

Peter Hotez and the public health issue of online harassment

Vir antibody drug aimed at influenza A fails in clinical trial

Duchenne breakthrough therapy leaves behind pioneering families

HHS names first

focus

Ending racial health disparities hinges on penalties, political will

EF3 tornado rips through North Carolina amid extreme weather nationwide

Stanford president's case begs question: Who takes blame?

Generative AI mines health records to identify patients’ social needs

Tesla recalling nearly 16,000 of its 2021

7 more heat

hotspot

hotspot

entertainment

focus